Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement
      Treatment Decision Making in Relapsed/Refractory Multiple Myeloma : Episode 4

      Navigating MM Treatment: Sequencing Strategies and Integrating Talquetamab

      June 19, 2024
      By Donna Catamero, ANP-BC, OCN, CCRC
      Beth Faiman, PhD
      • Tiffany Richards, PhD, ANP-BC

      News
      Video

      This session explores clinical evidence for sequencing treatments in MM, highlighting the safety profile of talquetamab as a potential tool in your MM patient management.

      EP: 1.Case Study: 63-Year-Old Man With Multiple Myeloma

      EP: 2.Empowering Patients With Myeloma Through Resources

      EP: 3.Clinical Scenario: Treating Late-Line Relapsed Multiple Myeloma

      Now Viewing

      EP: 4.Navigating MM Treatment: Sequencing Strategies and Integrating Talquetamab

      EP: 5.Strategies for Discussing Potential Adverse Effects of Talquetamab in MM

      EP: 6.Managing Toxicities From Talquetamab in Multiple Myeloma

      EP: 7.Integrating GPRC5D-Targeting Bispecifics for Relapsed/Refractory MM

      EP: 8.Clinical Advice on Caring for Patients Treated With Talquetamab

      EP: 9.Insights on Evolving Treatment Strategies for Multiple Myeloma

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman wearing a patterned shirt in front of a dark blue background
      Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
      Photo of a woman with dark curly hair wearing a floral shirt
      Image of a woman with gray hair on a light blue background
      Photo of a woman with a blue border around the image
      Image of a woman with dark hair wearing a floral shirt in front of a blurred background
      Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
      Related Content
      Line illustration of blood cells on a blue background

      Teclistamab Safe, Effective for Older Adults With Multiple Myeloma

      Roman Fabbricatore
      May 26th 2025
      Article

      CRS and ICANS rates were similar in adults 75 years or older vs younger individuals with relapsed/refractory multiple myeloma.

      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

      PDF of Rx Road Map for subcutaneous daratumumab in multiple myeloma

      Rx Road Map: Subcutaneous Daratumumab in Multiple Myeloma

      Sylwia Zielinska, RN
      Published: May 7th 2025 | Updated: June 5th 2025
      Article

      A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.

      Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

      Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

      Lindsay Fischer
      April 13th 2023
      Podcast

      Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

      Image of red blood cells

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Ashling Wahner
      April 22nd 2025
      Article
      Image of red blood cells

      Daratumumab Decreased Progression Risk in High-Risk Smoldering MM

      Jax DiEugenio
      April 19th 2025
      Article

      Daratumumab showed a decrease in disease progression or death risk vs active monitoring in patients with high-risk smoldering multiple myeloma.

      Related Content
      Line illustration of blood cells on a blue background

      Teclistamab Safe, Effective for Older Adults With Multiple Myeloma

      Roman Fabbricatore
      May 26th 2025
      Article

      CRS and ICANS rates were similar in adults 75 years or older vs younger individuals with relapsed/refractory multiple myeloma.

      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

      PDF of Rx Road Map for subcutaneous daratumumab in multiple myeloma

      Rx Road Map: Subcutaneous Daratumumab in Multiple Myeloma

      Sylwia Zielinska, RN
      Published: May 7th 2025 | Updated: June 5th 2025
      Article

      A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.

      Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

      Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

      Lindsay Fischer
      April 13th 2023
      Podcast

      Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

      Image of red blood cells

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Ashling Wahner
      April 22nd 2025
      Article
      Image of red blood cells

      Daratumumab Decreased Progression Risk in High-Risk Smoldering MM

      Jax DiEugenio
      April 19th 2025
      Article

      Daratumumab showed a decrease in disease progression or death risk vs active monitoring in patients with high-risk smoldering multiple myeloma.

      Latest Conference Coverage

      Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer

      Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.